IDO1 Inhibition Promotes Activation of Tumor-intrinsic STAT3 Pathway and Induces Adverse Tumor-protective Effects

Area of Science:

• Immunology
• Cancer Biology
• Pharmacology

Background:

• Pharmacological inhibition of Indoleamine 2,3-dioxygenase 1 (IDO1) is a promising cancer therapy strategy.
• Phase III clinical trial failures necessitate understanding the underlying mechanisms of IDO1 inhibitors' inefficacy.
• Investigating the tumor microenvironment is crucial for comprehending IDO1 inhibitor responses.

Purpose of the Study:

• To elucidate the comprehensive effects of apo-IDO1 inhibitors on the tumor microenvironment.
• To identify the reasons for the clinical failure of IDO1 inhibitors in cancer treatment.
• To explore potential combination strategies for enhancing IDO1 inhibitor efficacy.

Main Methods:

• Single-cell RNA sequencing was employed to analyze the tumor microenvironment response.
• The study utilized a mouse model of colon cancer (CT26 cells in BALB/C mice).
• Analysis focused on immune cell activation, macrophage infiltration, and cytokine signaling.

Main Results:

• Apo-IDO1 inhibitors activated intratumoral immune cells, including T cells, macrophages, and NK cells.
• These inhibitors also promoted M2 macrophage infiltration and IL-6 secretion by monocytes and macrophages.
• Tumor cells exhibited activation of the JAK2/STAT3 signaling pathway, enhancing survival.
• This activation occurred despite heightened immune cell activity, contributing to treatment failure.

Conclusions:

• Apo-IDO1 inhibitors have unforeseen adverse effects on tumor cells by activating pro-survival pathways.
• The IL-6/JAK2/STAT3 signaling pathway plays a critical role in tumor cell resistance to IDO1 inhibition.
• Combining IL-6/JAK2/STAT3 inhibitors with apo-IDO1 inhibitors may improve therapeutic outcomes in cancer treatment.